The cutthroat battle for the US weight-loss drug market
MAR 23 - When Ruth Gonzalez decided to start taking the weight-loss medicine Zepbound last year, she first had to find a way to afford its roughly $350 Kenya breaking news | Kenya news today |..
✨ Key Highlights
A fierce competition is unfolding in the US weight-loss drug market, characterized by significant price cuts and direct-to-consumer sales as drugmakers struggle to gain traction due to a lack of widespread insurance coverage.
- Drugmakers like Eli Lilly and Novo Nordisk have slashed prices, with some doses of Wegovy now costing $149 a month, down from over $1,600.
- Patients like Ruth Gonzalez are making financial sacrifices to afford these medications, which are often not covered by insurance.
- The direct-to-consumer model, highlighted by the new TrumpRx website, aims to make pricing more transparent and bypass traditional price negotiators.
Continue Reading
Read the complete article from Capital Business
Part of the Day's Coverage
War, supply chains, and the case for Africa's pharmaceutical manufacturing - March 2026
Recent geopolitical conflicts, particularly in the Middle East, are significantly disrupting global pharmaceutical supply chains, leading to increased costs and potential shortages of medicines in Africa. The National Farmers Union in the UK has warned that rising fuel and fertilizer costs, driven by the Iran conflict and the blockade of the Strait of Hormuz, will likely lead to increased food prices. Meanwhile, a fierce competition is unfolding in the US weight-loss drug market, characterized by significant price cuts and direct-to-consumer sales as drugmakers struggle to gain traction due to a lack of widespread insurance coverage.
